|
[Related PubMed/MEDLINE]
Total Number of Papers: 1015
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: hERG |
| Long Form |
: human ether-a-go-go-related gene |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Antimalarial activity assay of artesunate-3-chloro-4(4-chlorophenoxy) aniline in vitro and in mice models. |
4DTs, ADMET, ANOVA, ATS, ATSA, ED50, HIA, IC50, LuR, OECD, PQR, TI |
| 2 |
2023 |
Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. |
BBB, EPS, MD, TAAR1 |
| 3 |
2023 |
Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis. |
ASO, CF, LQT2, mRNA |
| 4 |
2023 |
DNA topoisomerase 2-associated proteins PATL1 and PATL2 regulate the biogenesis of hERG K+ channels. |
hiPSC-CMs |
| 5 |
2023 |
Elucidation of ALG10B as a Novel Long-QT Syndrome-Susceptibility Gene. |
ALG10B, LQTS |
| 6 |
2023 |
Ensemble of structure and ligand-based classification models for hERG liability profiling. |
LB, SB |
| 7 |
2023 |
Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action. |
APD, ECG, RyR2, SERCA2a |
| 8 |
2023 |
Evaluation of Some Safety Parameters of Dual Histamine H3 and Sigma-2 Receptor Ligands with Anti-Obesity Potential. |
ALAT, G-GT |
| 9 |
2023 |
hERG Blockade Prediction by Combining Site Identification by Ligand Competitive Saturation and Physicochemical Properties. |
cryo-EM, QSAR, SILCS |
| 10 |
2023 |
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers. |
CSFs, ECM |
| 11 |
2023 |
Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment. |
--- |
| 12 |
2023 |
In silico mechanisms of arsenic trioxide-induced cardiotoxicity. |
APL, ATO, ENDO, EPI, MCELL, VMs |
| 13 |
2023 |
In silico prediction of hERG blockers using machine learning and deep learning approaches. |
GCNs, ML |
| 14 |
2023 |
Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers. |
GBM |
| 15 |
2023 |
Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat. |
ECG |
| 16 |
2023 |
Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature. |
LAAM |
| 17 |
2023 |
Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects. |
APD90, CiPA, CV, EAD, HR, hSCCMs, ISO, LCAL, MEA, PES, SR, VT |
| 18 |
2022 |
A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. |
--- |
| 19 |
2022 |
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. |
PDE10A |
| 20 |
2022 |
Automatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study. |
--- |
| 21 |
2022 |
BayeshERG: a robust, reliable and interpretable deep learning model for predicting hERG channel blockers. |
--- |
| 22 |
2022 |
Biphenyl scaffold for the design of NMDA-receptor negative modulators: molecular modeling, synthesis, and biological activity. |
NAM, NMDA |
| 23 |
2022 |
Cardiac Electropharmacological Effects of Antidiarrheal Drug Loperamide and Its Antidote Naloxone in Anesthetized Guinea Pigs. |
ECG, MAP |
| 24 |
2022 |
Cell-Based hERG Channel Inhibition Assay in High-Throughput Format. |
--- |
| 25 |
2022 |
Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs. |
CTSB, CUK, DN, PEG |
| 26 |
2022 |
Discovery of 2-vinyl-10H-phenothiazine derivatives as a class of ferroptosis inhibitors with minimal human Ether-a-go-go related gene (hERG) activity for the treatment of DOX-induced cardiomyopathy. |
SAR |
| 27 |
2022 |
Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity. |
FGFR3 |
| 28 |
2022 |
Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. |
hiPSC-CMs, SGK1 |
| 29 |
2022 |
Establishment of human embryonic stem cell WAe009-A-74 carrying a Long QT syndrome mutation in KCNH2. |
LQT2 |
| 30 |
2022 |
HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models. |
LQTS |
| 31 |
2022 |
High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition. |
CV, NCATS, qHTS |
| 32 |
2022 |
Identification and New Indication of Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist Derived from Machine Learning and Transcriptome-Based Drug Repositioning Approaches. |
LDLR, MCHR1, NASH |
| 33 |
2022 |
Identification of novel bioactive compounds from Olea europaea by evaluation of chemical compounds in the OliveNet™ library: in silico bioactivity and molecular modelling, and in vitro validation of hERG activity. |
P-gp, SMD |
| 34 |
2022 |
In-situ and amplification-free imaging of hERG ion channels at single-cell level using a unique core-molecule-shell-secondary antibody SERS nanoprobe. |
SERS |
| 35 |
2022 |
Inhibition of human ether-a-go-go-related gene K+ currents expressed in HEK293 cells by three gingerol components from ginger. |
--- |
| 36 |
2022 |
Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism. |
--- |
| 37 |
2022 |
Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent. |
CNS, IND |
| 38 |
2022 |
Ion channel model reduction using manifold boundaries. |
MBAM |
| 39 |
2022 |
Lead optimization of pyrido[2,3-d][1]benzazepin-6-one derivatives leading to the discovery of a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) antagonist (DS69910557). |
hPTHR1 |
| 40 |
2022 |
Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques. |
SMOTE |
| 41 |
2022 |
Loperamide-Induced Torsades de Pointes. |
--- |
| 42 |
2022 |
Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. |
diLQTS, TdP |
| 43 |
2022 |
Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K + Channel by Tolterodine. |
--- |
| 44 |
2022 |
Mutagenicity and safety pharmacology of a standardized antidiabetic polyherbal formulation. |
DRF, FOB, MN |
| 45 |
2022 |
Pharmacological characterisation of electrocardiogram J-Tpeak interval in conscious Guinea pigs. |
QT, TdP |
| 46 |
2022 |
Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy. |
Ang II, PCH |
| 47 |
2022 |
Pore opening, not voltage sensor movement, underpins the voltage-dependence of facilitation by a hERG blocker. |
--- |
| 48 |
2022 |
Predicting hERG channel blockers with directed message passing neural networks. |
D-MPNN |
| 49 |
2022 |
Repurposing drugs as COVID-19 therapies: A toxicity evaluation. |
CPE, PLD, SARS-CoV-2 |
| 50 |
2022 |
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity. |
--- |
| 51 |
2022 |
Structural modeling of the hERG potassium channel and associated drug interactions. |
--- |
| 52 |
2022 |
Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics. |
--- |
| 53 |
2022 |
The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels. |
AP, CiPA, ECG |
| 54 |
2022 |
The Linkage Phase of the Polymorphism KCNH2-K897T Influences the Electrophysiological Phenotype in hiPSC Models of LQT2. |
hiPSC-CMs, hiPSCs, LQT2, SNP |
| 55 |
2022 |
Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays. |
siRNA |
| 56 |
2022 |
Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K+ Channel. |
--- |
| 57 |
2022 |
Vicious LQT induced by a combination of factors different from hERG inhibition. |
APD, EADs, ECG, LQT, TdP, VF |
| 58 |
2021 |
2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system. |
ECG, LVDP, NPSs, PAK1 |
| 59 |
2021 |
A Phase 1 Study to Investigate the Effects of Cortexolone 17alpha-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity. |
--- |
| 60 |
2021 |
Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers. |
CI, QTcF |
| 61 |
2021 |
Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. |
AD, LQTS, TdP |
| 62 |
2021 |
Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. |
CRC |
| 63 |
2021 |
Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. |
AMPK, mTOR, PCSK9 |
| 64 |
2021 |
Cardiotoxicity assessment using 3D vascularized cardiac tissue consisting of human iPSC-derived cardiomyocytes and fibroblasts. |
ADD, hiPSC-CMs, MCS |
| 65 |
2021 |
Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. |
FQs, HCQ, SAES-CoV-2 |
| 66 |
2021 |
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. |
LQTS |
| 67 |
2021 |
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. |
KRAS, MAPK, NF-1, PK, RTK, SH2 |
| 68 |
2021 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect. |
DA |
| 69 |
2021 |
Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives. |
GPR119 |
| 70 |
2021 |
Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach. |
HBA |
| 71 |
2021 |
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. |
EZH2, SAR |
| 72 |
2021 |
Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. |
MIC |
| 73 |
2021 |
Disruption of protein quality control of the human ether-a-go-go related gene K+ channel results in profound long QT syndrome. |
hiPSC-CMs, LQTS, RNF207 |
| 74 |
2021 |
Dual Mechanisms of Cardiac Action Potential Prolongation by 4-Oxo-Nonenal Increasing the Risk of Arrhythmia; Late Na+ Current Induction and hERG K+ Channel Inhibition. |
4-HNE, 4-ONE, APD, INaL |
| 75 |
2021 |
Flavonoids and hERG channels: Friends or foes? |
--- |
| 76 |
2021 |
Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation. |
ECG, hiPSC-CMs, MAP |
| 77 |
2021 |
hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation. |
CM, hESC, LQT2, MEA |
| 78 |
2021 |
Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes. |
CM, EAD, iPSC, LQT3 |
| 79 |
2021 |
Investigation of PAS and CNBH domain interactions in hERG channels and effects of long-QT syndrome-causing mutations with surface plasmon resonance. |
CNBH, LQTS, PAS, SPR |
| 80 |
2021 |
L51P, a novel mutation in the PAS domain of hERG channel, confers long QT syndrome by impairing channel activation. |
LQTS, MD, PAS, PME |
| 81 |
2021 |
Mechanisms of gefitinib-induced QT prolongation. |
APD, NSCLC |
| 82 |
2021 |
Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. |
NCEs |
| 83 |
2021 |
Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. |
ALK2, BMP |
| 84 |
2021 |
Parallel Recordings of Transmembrane hERG Channel Currents Based on Solvent-Free Lipid Bilayer Microarray. |
BLMs, Si |
| 85 |
2021 |
Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. |
COVID-19, SARS-CoV-2 |
| 86 |
2021 |
Pharmacological corrections of the mutant hERG channels by posaconazole. |
HEK, WT |
| 87 |
2021 |
Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis. |
5-HT, AEs |
| 88 |
2021 |
Proarrhythmic effects induced by benzethonium chloride and domiphen bromide in vitro and in vivo. |
BZT, DMP, hiPSC-CMs |
| 89 |
2021 |
Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. |
--- |
| 90 |
2021 |
Refinement of a cryo-EM structure of hERG: Bridging structure and function. |
MDFF, VSD |
| 91 |
2021 |
Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG‑A561V protein. |
CNX, CRT, ERP57, WT |
| 92 |
2021 |
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. |
CNS |
| 93 |
2021 |
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. |
TB |
| 94 |
2021 |
Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. |
IFs, SVM |
| 95 |
2021 |
The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031. |
--- |
| 96 |
2021 |
TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction. |
RMSE, rs, SVR |
| 97 |
2020 |
AKAP5 anchors PKA to enhance regulation of the HERG channel. |
AKAPs, beta-AR, LQTS, PKA |
| 98 |
2020 |
Assessment of spatial heterogeneity of ventricular repolarization after multi-channel blocker drugs in healthy subjects. |
SHVR |
| 99 |
2020 |
Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. |
hAMCase |
| 100 |
2020 |
Critical Assessment of Artificial Intelligence Methods for Prediction of hERG Channel Inhibition in the "Big Data" Era. |
AI, DNNs, RNNs |
|
A Search Service for Abbreviation / Long Form
